Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational Study

[1]  C. Shimizu,et al.  Genetic polymorphisms of lysophosphatidic acid receptor 1 are associated with the onset of taxane-induced peripheral neuropathy. , 2021, British Journal of Anaesthesia.

[2]  M. Sumitani,et al.  Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis , 2021, Scientific Reports.

[3]  D. Hemmings,et al.  Signalling by lysophosphatidate and its health implications. , 2020, Essays in biochemistry.

[4]  M. Kurano,et al.  Establishment of a Measurement System for Sphingolipids in the Cerebrospinal Fluid Based on Liquid Chromatography-Tandem Mass Spectrometry, and Its Application in the Diagnosis of Carcinomatous Meningitis. , 2020, The journal of applied laboratory medicine.

[5]  M. Sumitani,et al.  Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model , 2019, Scientific Reports.

[6]  M. Kurano,et al.  Evaluation of Lysophospholipid Measurement in Cerebrospinal Fluid Samples using Liquid Chromatography-Tandem Mass Spectrometry. , 2019, Lipids.

[7]  Sakae Tanaka,et al.  Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis , 2019, Scientific Reports.

[8]  Ke Yang,et al.  Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury: A Review and Meta-Analysis of Randomized Controlled Trials , 2019, The Clinical journal of pain.

[9]  P. Wiffen,et al.  Pregabalin for neuropathic pain in adults. , 2019, The Cochrane database of systematic reviews.

[10]  M. Sumitani,et al.  Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study , 2018, PloS one.

[11]  Martin Underwood,et al.  Low back pain: a call for action , 2018, The Lancet.

[12]  松岡 峰造.  Neurotropin® Accelerates the Differentiation of Schwann Cells and Remyelination in a Rat Lysophosphatidylcholine-Induced Demyelination Model , 2018 .

[13]  H. Yoshikawa,et al.  Neurotropin® Accelerates the Differentiation of Schwann Cells and Remyelination in a Rat Lysophosphatidylcholine-Induced Demyelination Model , 2018, International journal of molecular sciences.

[14]  K. Safranow,et al.  Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters , 2017, Lipids in Health and Disease.

[15]  M. Sumitani,et al.  Direct evidence of central nervous system axonal damage in patients with postoperative delirium: A preliminary study of pNF-H as a promising serum biomarker , 2017, Neuroscience Letters.

[16]  M. Dowling,et al.  Endogenous lysophosphatidic acid (LPA1) receptor agonists demonstrate ligand bias between calcium and ERK signalling pathways in human lung fibroblasts , 2017, British journal of pharmacology.

[17]  H. Ueda.  Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. , 2017, Pain.

[18]  M. Teixeira,et al.  Trial of Pregabalin for Acute and Chronic Sciatica , 2017, The New England journal of medicine.

[19]  M. Sumitani,et al.  Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. , 2016, Biomedical reports.

[20]  M. Morales-Suárez-Varela,et al.  Preventive Analgesia with Pregabalin in Neuropathic Pain from “Failed Back Surgery Syndrome”: Assessment of Sleep Quality and Disability. , 2015, Pain medicine.

[21]  H. M. Geller,et al.  Cooperative interactions of LPPR family members in membrane localization and alteration of cellular morphology , 2015, Journal of Cell Science.

[22]  Sakae Tanaka,et al.  Elevated levels of phosphorylated neurofilament heavy subunit in the cerebrospinal fluid of patients with lumbar spinal stenosis: preliminary findings. , 2015, The spine journal.

[23]  M. Sumitani,et al.  Potential Role of pNF-H, a Biomarker of Axonal Damage in the Central Nervous System, as a Predictive Marker of Chemotherapy-Induced Cognitive Impairment , 2015, Clinical Cancer Research.

[24]  S. Fishman,et al.  An Interprofessional Consensus of Core Competencies for Prelicensure Education in Pain Management: Curriculum Application for Physical Therapy , 2013, Physical Therapy.

[25]  Lin Ma,et al.  An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model , 2013, Molecular pain.

[26]  A. Bräuer,et al.  Current views on regulation and function of plasticity-related genes (PRGs/LPPRs) in the brain. , 2013, Biochimica et biophysica acta.

[27]  B. Laurent,et al.  The specific disease burden of neuropathic pain: Results of a French nationwide survey , 2011, PAIN.

[28]  J. Ochoa,et al.  NEUROPATHIC PAIN: REDEFINITION AND A GRADING SYSTEM FOR CLINICAL AND RESEARCH PURPOSES , 2009, Neurology.

[29]  Bernard Laurent,et al.  Prevalence of chronic pain with neuropathic characteristics in the general population , 2008, PAIN.

[30]  J. Dostrovsky,et al.  Neuropathic pain , 2008, Neurology.

[31]  Lin Ma,et al.  Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain , 2008, Molecular pain.

[32]  Misha-Miroslav Backonja,et al.  Classification of patients with pain based on neuropathic pain symptoms: Comparison of an artificial neural network against an established scoring system , 2007, European journal of pain.

[33]  H. Ueda.  Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. , 2006, Pharmacology & therapeutics.

[34]  H. Ueda,et al.  Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling , 2004, Nature Medicine.

[35]  Chantal Wouters,et al.  An exploratory study , 2003 .

[36]  H. Arai,et al.  Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species , 2000, FEBS letters.